Close Menu

NEW YORK (360Dx) – Interpace Diagnostics reported after the close of the market on Monday that its first quarter revenues rose 25 percent year over year.

For the three months ended March 31, the firm reported revenues of $6.0 million, up from $4.8 million in the year-ago quarter, but missed the consensus Wall Street estimate of $6.3 million.

Interpace President and CEO Jack Stover said in a statement that the firm had a strong start to the year, driven in part by increasing sales volumes for its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.